Las opiniones expresadas por los colaboradores de Entrepreneur son personales. Al igual que las computadoras, los seres h...
Our DNA data is being abused
DNA data is very important, since it encodes not only our blueprint, but that of our family and children. The continuing privacy and the security of people’s genetic data, both immediately, and into the long term, is of paramount importance.
Today, consumers unknowingly forfeit ownership of their DNA to home DNA testing companies, Big Pharma and other third parties.
This has led to the commoditization of DNA and allows our DNA data to be bought and sold by third parties just like traditional data; but unlike your password or credit card number, your DNA cannot be changed. 65% of people willing to take a DNA test have expressed privacy concerns, with almost all expressing concerns with the idea of any company owning their genomic profile.
Every year, drugmakers like GlaxoSmithKline, Procter & Gamble and Pfizer spend millions to obtain records from testing companies. Although these deals are legal, user consent is obtained unethically through confusing terms and conditions and weak privacy policies. After sold to Big Pharma, our DNA is utilized for medical research and accelerating data-driven drug discovery. Although this is a positive result of the Genomic Revolution, our DNA is licensed and sold without our knowledge or benefit.
Genobank.io: providing an incognito and secure way to store DNA data
Genobank is the first privacy-preserving personal DNA Kit that guarantees consumers complete ownership and control over their DNA. Our patent pending technology leverages blockchain and differential privacy to anonymize your DNA data while making it available for analysis. Your datasets are then stored inside an encrypted DNA Wallet that is only accessible to you. (private data capsule).
For the first time ever, consumers can have their DNA tokenized and stored with confidence with our patent pending technology. This will allow users to enforce privacy laws by allowing them to check 3rd party DNA databases for unauthorized copies of their DNA data. Even if the data is de-identified (SNPs matching).
They can also control who they share data with by selecting from a series of verified scientific and medical facilities, and can be rewarded with tokens by participating in clinical trials or health studies.
Virtually unhackable, decentralized and encrypted to protect your DNA data
Since there is only one private DNA Wallet per user, third parties will never have access to your DNA data without your explicit consent (digital signature). Only you can grant/revoke access and modify/delete biodata & records. YOU are in control!
Individual users and Families will have the option to create a unique DNA fingerprint, receive results for early disease identification, participate in clinical trials, get advice from a Genetic Counselor, donate your data to accelerate scientific discoveries and in the near future track a serialized set of your RNA data to see how it changes over time (epigenetics).
- Setup ‘DNA Wallet’ - Your DNA Wallet will be used to securely store and access your Genetic map. Each user has their own wallet that is only accessible with a private pin code.
- Submit DNA - We send a saliva collection kit for you to submit your biospecimen and ship it back to an approved lab. Each lab is reviewed and certified to insure they abide by our privacy policies. Each tube is referenced with the unique address (QR Code) of your personal DNA Wallet.
- Sequencing - The lab receives your biospecimen and sequences your DNA.,
- Tokenization - A unique ID is created as a Non-fungible-token (NFT) and recorded into the blockchain. Throughout this process, you’re registered as exclusive owner of your DNA data. (Patent pending).
- Access - Your encrypted DNA data is made available through your personal Wallet. No one will ever have unauthorized access to these records (not even GenoBank.io)
- Sharing (optional) - This feature requires your explicit consent to be used and is turned off by default. Our platform hosts genetic counselors, bioinformaticians and data scientists that can request access for these types of projects. Pharmaceutical companies can also inquire to rent your data for commercial use.
Working with trusted partners to secure your data
In order to ensure we create the most secure platform for our users, GenoBank has partnered with Oasis Labs, a blockchain platform providing top-notch privacy for user data. Oasis Labs has developed new ‘privacy preserving’ cloud that makes medical information more easily shared and accessible to researchers while preserving privacy using enclaves (SGX).
Currently Genobank.io has more than 400 users in the waiting list, including more than 20 member our own families.
We are currently in beta with RIO, a chain of health clinics that serve approximately 1000 patients a month. The beta started in Q4 of 2019 with 7 clinics. We developed a Co-Branded DNA kit (White-label) with the objective of helping patients receive a polygenic risk score related to Type 2 familial diabetes based our advisors Prof. Karol Estrada’s research.
With our investors support, we will invest enough efforts to reach our first 2000 to 3000 users by the end of 2020.
Protecting our customers
GenoBank has a variety of customers, ranging from individual users and families interested in sequencing their DNA and explore their genetic traits to the data scientists who require genomic information to best process and understand new data-driven drugs, treatments and disease. Our goal is to provide a safe, privacy-preserving platform for users to sequence and share their DNA and collaborate with the scientific community to achieve the Genomic Revolution together!
Genobank.io aims to become the first privacy-preserving DNA test provider that treats its users as data partners and enable other companies to launch their own branded DNA Test Kits.
Sources of Revenue:
Direct-to-consumer model: Selling Privacy-preserving DNA kits online & via kiosks at drug stores, wellness and fitness centers, airports, malls, etc
Enterprise model: Selling a White Label version of our DNA kits and platform to health clinics, genetic counselors, nutritionists and hospitals. (Any company that needs temporary access to DNA data from their clients to personalize a service without being a custodian of it). Genobank allows health clinics and hospitals launch their own branded DNA test kits.
+$20 Billion market opportunity
The global direct-to-consumer genetic testing (DTC-GT) market is forecast to grow steadily to be worth over US$1bn by 2020. Genetic Testing Market size is estimated to exceed USD 25 billion by 2025 and it’s predicted that 15% of the world’s population will have had their genome sequenced willing to take them 65% have expressed considered privacy concerns, with almost all expressing concerns with a company owning their genomic profile.
We believe the most important driver to escale over 100 Million users are:
Data privacy, scientific accuracy, and to create an appropriate digital ecosystem to support any psychological impact appropriately (Privacy-preserving communication channel with Genetic Counselors).
A first to market, only player in this space
GenoBank.io is the only option available that has 3 patents (pending) over decentralized DNA data management platforms, designed to protect your DNA data and identity. We use blockchain at its full potential by registering your DNA data as a unique digital asset also known as a non-fungible-token (NFT). This grants you exclusive ownership over it.
Unlike existing options, our patent-pending solution allows:
Pharmaceutical companies now have a process to ethically and systematically rent genetic records directly from the DNA owners.
Patients suffering from undiagnosed illnesses and diseases now can benefit from finding dna-based clinical trials without risking their identities.
Our network will protect users from government warrants and legal overrides.
Democratizing access to Data-Driven Medicine.
By reaching our investment goal, additionally to our privacy-preserving DNA Wallets; GenoBank.io plans to deploy DNA test kit ATMs; This will be world’s first DNA test kit that are available for purchase via kiosks. Our machines are patent-pending and will be located at drug stores, airports, malls, wellness and fitness centers, etc. No personal information will be involved when using a kiosk. This will democratize access to DNA test kits while completely protecting user privacy and security. Genobank.io will enable users to sequence their DNA even without a smartphone by using a paper DNA Wallets and PalmID to interact with the platform.
Genobank.io has raised today $215,000 USD from angel investors. With this investment we’ve build out our first working DNA wallet (please visit http://genobank.me) based on one of our 3 patent pending architectures while working with experts in the fields of genomics, privacy laws, distributed cloud/storage platforms and blockchain technologies.
Genobank.io also got funded by Oasis Labs (token funding) as a part of their partner program.
Genobank.io was also selected to be part of Sony Entertainment "Meet The Drapers" Season 3 (to be aired Mid January 2020).
Led by data privacy, blockchain and genomics industry experts
Daniel Uribe, MBA
CEO & Co Founder of Genobank.io, Serial Entrepreneur, Sun Microsystems Alumni, Unix Expert, +15 years experience in Cybersecurity, Cloud Computing; +4 years experience in Blockchain & Smart Contracts. Recently specializes in Privacy Laws, Genomics & Bioinformatics. Holds Bs. Electronics Engineering, MBA from IPADE Business School, Executive Programs @ Stanford GSB, Singularity University; Data Science at Galvanize & RNAseq at EcSeq Bioinformatics GmbH (Berlin).
PhD Candidate, Computer Science, MS in Electrical and Electronic
Founding advisor of this Genobank.io, design and implementation of a RexChain fork to persist encrypted DNA data on a separated storage layer, accessible via a wallet.
Behind the front-end or API, is a platform that houses real time analytics with patient - medic - drug interactions and caters to the pharmaceutical industry, insurance providers and hospital administrators.